Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;112(5):723-730.
doi: 10.1111/ejh.14163. Epub 2023 Dec 28.

Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system

Melanie Lopez  1 , Radhika Kainthla  2   3 , Susana Lazarte  3   4 , Weina Chen  5 , Ank E Nijhawan  3   4 , Sheena Knights  3   4
Affiliations

Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system

Melanie Lopez et al. Eur J Haematol. 2024 May.

Abstract

Objective: To describe cases of Kaposi's sarcoma-associated herpesvirus (KSHV)-associated multicentric Castleman's disease (MCD) and primary effusion lymphoma (PEL) in patients with HIV from a large, safety-net hospital system in Dallas, Texas, USA.

Methods: We conducted a retrospective review of patients with HIV-associated PEL and/or MCD.

Results: Twelve patients with PEL and 10 patients with MCD were identified. All patients were male and 17 of 20 were men who have sex with men; 66.7% of PEL patients and 50% of MCD patients had concurrent KS at the time of diagnosis; 42% of patients with PEL and 20% of patients with MCD died during the follow-up period. We noted improved survival in our cohort compared to previous studies, particularly in our PEL patients with a median survival of 11.4 months compared to 3-6-month median survival historically. Median follow-up time for MCD patients was 17.5 months. This improved survival is despite suboptimal antiretroviral therapy (ART) adherence at diagnosis, with only 50% of patients on ART at the time of MCD/PEL diagnosis.

Conclusion: These data highlight the importance of early recognition of PEL and MCD, and the larger-scale efforts needed to better understand the pathogenetic drivers of clinical outcomes in patients affected by KSHV-related diseases.

Keywords: Castleman's disease; HIV; human herpesvirus‐8; primary effusion lymphoma.

PubMed Disclaimer

References

REFERENCES

    1. Shimada K, Hayakawa F, Kiyoi H. Biology and management of primary effusion lymphoma. Blood. 2018;132(18):1879‐1888. doi:10.1182/blood‐2018‐03‐791426
    1. Castillo JJ, Shum H, Lahijani M, Winer ES, Butera JN. Prognosis in primary effusion lymphoma is associated with the number of body cavities involved. Leuk Lymphoma. 2012;53(12):2378‐2382.
    1. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome‐related lymphoma with dose‐adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101(12):4653‐4659.
    1. Ramos JC, Sparano JA, Chadburn A, et al. Impact of Myc in HIV‐associated non‐Hodgkin lymphomas treated with EPOCH and outcomes with vorinostat (AMC‐075 trial). Blood. 2020;136(11):1284‐1297.
    1. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma‐associated herpesvirus‐like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276‐1280.

Supplementary concepts

LinkOut - more resources